Skip to main content

Table 1 Definition of responders (change of oxygenation) to treatment depending on the patient’s condition

From: Prospective evaluation of hydroxychloroquine in pediatric interstitial lung diseases: Study protocol for an investigator-initiated, randomized controlled, parallel-group clinical trial

Patient’s conditionMeasured parametersDefinition of significant change or responder to the initiation of hydroxychloroquine (HCQ)Definition of significant change or responder to the withdrawal of HCQMethod of aggregation
In room airSaO2
Respiratory rate
Increase ≥ 5% in O2 Sat,
or
Decrease in resp. rate ≥ 20%
Decrease ≥ 5% in O2 Sat,
or
Increase in resp. rate ≥ 20%
Proportion of responders
Using O2 supplementSaO2 withdrawal
Respiratory rate
Increase ≥ 5% in O2 Sat
or
Decrease in resp. rate ≥ 20%
or
Support no longer needed
Decrease ≥ 5% in O2 Sat,
or
Increase in resp. rate ≥ 20%
or
Support newly needed
Proportion of responders
Using high-flow nasal cannulaO2 flow, air flowDecrease ≥ 20%
or
Support no longer needed
Increase ≥ 20%
or
Support newly needed
Proportion of responders
VentilatedOxygenation indexDecrease ≥ 20%
or
Support no longer needed
Increase ≥ 20%
or
Support newly needed
Proportion of responders